ArticleJournal of neuro-oncology2025
Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Low-energy X-ray intraoperative radiotherapy for brain metastases: a systematic review of efficacy and safety.Journal of neuro-oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDue to significantly lower neurocognitive toxicity, whole-brain irradiation (WBI) has largely been replaced by focal irradiation of the resection cavity following brain metastasis surgery. However, the optimal treatment modality and fractionation scheme remain controversial. This study conducts a comparative analysis of hypofractionated stereotactic radiotherapy (HSRT) and intraoperative radiotherapy (IORT), focusing on clinical outcomes and toxicity profiles.
methodsA retrospective cohort study was conducted, analyzing 129 patients (HSRT: 72, IORT: 57) with 137 treated cavities (HSRT: 75, IORT: 62) at the University Hospital of Augsburg (UKA) between 2013 and 2021. Baseline characteristics, oncological outcomes, incidence of radionecrosis (RN), and time to further treatment were compared.
resultsRadionecrosis occurred significantly less frequently in the IORT group compared to HSRT, with 1-year RN rates of 3.7% (95% CI: 0.5-23.5%) and 21.8% (95% CI: 11.7-39.2%), respectively (p = 0.00025). At two years, the RN rate remained substantially lower after IORT (8.5% vs. 53.2%). Notably, in patients without prior cerebral irradiation, no symptomatic RN (sRN) occurred following IORT, whereas the 2-year sRN rate in the HSRT group reached 35.5% (p = 0.0036). Oncological outcomes, including overall survival (OS), local control (LC), intracranial disease control, leptomeningeal dissemination (LMD), and WBI avoidance, were comparable between the two groups. However, distant brain control (DBC) at one year was higher in the HSRT group. While HSRT was initiated after a median delay of 29 days (range: 14-71), IORT was delivered intraoperatively, enabling immediate continuation of systemic therapy.
conclusionIn this retrospective single-center analysis, IORT demonstrated comparable oncological efficacy to HSRT while significantly reducing the risk of RN. Given its intraoperative delivery and the ability to promptly resume systemic therapy, and the precise application directly at the resection cavity, IORT may represent a practical and effective alternative in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.